Mediclinic International (MDC) Downgraded by UBS Group to Neutral
Mediclinic International (LON:MDC) was downgraded by investment analysts at UBS Group to a “neutral” rating in a report issued on Tuesday, www.digitallook.com reports. They currently have a GBX 650 ($9.13) target price on the stock, up from their previous target price of GBX 600 ($8.43). UBS Group’s price target would indicate a potential upside of 8.84% from the stock’s current price.
MDC has been the subject of several other reports. JPMorgan Chase & Co. cut shares of Mediclinic International to a “neutral” rating and decreased their price objective for the company from GBX 898 ($12.61) to GBX 733 ($10.29) in a research note on Thursday, October 19th. Citigroup restated a “neutral” rating on shares of Mediclinic International in a research note on Tuesday, October 24th. Credit Suisse Group decreased their price objective on shares of Mediclinic International from GBX 783 ($11.00) to GBX 630 ($8.85) and set a “neutral” rating for the company in a research note on Monday, November 20th. Macquarie decreased their price objective on shares of Mediclinic International from GBX 760 ($10.67) to GBX 660 ($9.27) and set a “neutral” rating for the company in a research note on Friday, October 20th. Finally, Jefferies Group upgraded shares of Mediclinic International to a “buy” rating and lifted their price objective for the company from GBX 550 ($7.72) to GBX 616 ($8.65) in a research note on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of GBX 686.78 ($9.64).
Shares of Mediclinic International (LON MDC) opened at GBX 597.20 ($8.39) on Tuesday. Mediclinic International has a 12 month low of GBX 495.40 ($6.96) and a 12 month high of GBX 890.18 ($12.50). The company has a market cap of $4,400.00 and a P/E ratio of 6,635.56.
TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/mediclinic-international-mdc-downgraded-by-ubs-group-to-neutral/1835884.html.
Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.